Follow-up study for people treated with CAR-T therapy
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study checks how people do over the long term after receiving CAR-T, an advanced immune treatment. It may help doctors understand long-term safety and benefits, and what to expect after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have received CAR-T treatment (immune therapy using engineered cells).
- You took part in a Novartis CAR-T study or a University of Pennsylvania CAR-T study that works with Novartis.
- You have finished the original study or left it early for any reason.
- You agree to sign consent for this long-term follow-up study before joining.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study monitors participants who received a certain type of CAR T-cell therapy for cancer. It helps researchers understand long-term effects and safety.
This study checks in with people who already received CAR-T therapy to learn how they’re doing over time. It may help doctors understand the long-term benefits and side effects of CAR-T for future patients.
This study checks how people do over the long run after receiving a personalized, genetically modified CAR T cell treatment. It may help researchers understand long-term safety and outcomes, which can improve future care.
This study follows people who have already received a CRISPR CAR T cell therapy to monitor their long-term health and any side effects. It helps doctors understand how these treatments work over time.
This is a follow-up study for people age 18 or older who previously took part in a CAR T-cell gene therapy trial. It helps researchers check your health over time after that treatment and supports long-term safety and outcomes tracking.
This study is for people who previously received CAR T cells at the Dana-Farber/Harvard Cancer Center (DF/HCC). It mainly checks how you’re doing over the long term after treatment, and asks you to take part in follow-up visits or procedures.
Hear when a new Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.